Tissues were homogenized in radioimmunoprecipitation assay buffer (20 mM tris,150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM tetrasodium pyrophosphate, 1 mM β-glycerophosphate, and 1 mM sodium orthovanadate) containing
protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA) using a
Precellys sample lyzer (Bertin Technologies, Montigny le Bretonneux, France). Western blots were performed using standard procedures using antibodies against HMGB1 (1:1000,
ab18256, Abcam, Cambridge, UK), phospho-AKT S473 (1:1000,
CST 4060, Cell Signaling Technology, Danvers, MA, USA), total AKT (1:1000,
CST 9272, Cell Signaling Technology, Danvers, MA, USA), hemagglutinin (HA) (1:1000,
CST 3724 Cell Signaling Technology, Danvers, MA, USA), PPARγ (1:1000, C26H12, Cell Signaling Technology, Danvers, MA, USA), Myc-tag (1:1000, CST 2276, Cell Signaling Technology, Danvers, MA, USA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1: 2000,
ab181602, Abcam, Cambridge, UK), used as a loading control.
Detection of high–molecular weight proteins was performed using capillary electrophoresis (Wes, SimpleProtein, San Jose, CA, USA) using antibodies against FAS (CST 3189, Cell Signaling Technology, Danvers, MA, USA), ACC (CST 3662, Cell Signaling Technology, Danvers, MA, USA), and ACLY (
ab40793, Abcam, Cambridge, UK).
Personnaz J., Piccolo E., Dortignac A., Iacovoni J.S., Mariette J., Rocher V., Polizzi A., Batut A., Deleruyelle S., Bourdens L., Delos O., Combes-Soia L., Paccoud R., Moreau E., Martins F., Clouaire T., Benhamed F., Montagner A., Wahli W., Schwabe R.F., Yart A., Castan-Laurell I., Bertrand-Michel J., Burlet-Schiltz O., Postic C., Denechaud P.D., Moro C., Legube G., Lee C.H., Guillou H., Valet P., Dray C, & Pradère J.P. (2022). Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. Science Advances, 8(12), eabg9055.